Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. Both are novel synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection.
Company profile
Ticker
CLSN
Exchange
Website
CEO
Michael Tardugno
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CHEUNG LABORATORIES INC
SEC CIK
Corporate docs
Subsidiaries
CLSN Laboratories, Inc. • Celsion GmbH ...
IRS number
521256615
CLSN stock data
News
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
21 Jun 22
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
21 Jun 22
CLSN: OVATION 2 Study 85% Enrolled…
18 Jun 22
Celsion: Q1 Earnings Insights
16 May 22
Celsion Q1 EPS $(1.82) Misses $(0.99) Estimate, Sales $125.00K Beat $100.00K Estimate
16 May 22
Investment data
Securities sold
Number of investors
Calendar
16 May 22
12 Aug 22
31 Dec 22
Financial summary
| Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 34.36M | 34.36M | 34.36M | 34.36M | 34.36M | 34.36M |
| Cash burn (monthly) | (no burn) | 283.1K | 1.95M | 1.79M | 2.66M | 1.62M |
| Cash used (since last report) | n/a | 1.25M | 8.57M | 7.87M | 11.7M | 7.14M |
| Cash remaining | n/a | 33.12M | 25.79M | 26.49M | 22.66M | 27.22M |
| Runway (months of cash) | n/a | 117.0 | 13.2 | 14.8 | 8.5 | 16.8 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 18 Jul 22 | Goff Corinne Le | Common Stock | Grant | Acquire A | No | No | 0 | 53,000 | 0 | 53,000 |
| 18 Jul 22 | Goff Corinne Le | Stock Option Common Stock | Grant | Acquire A | No | No | 1.95 | 177,000 | 345.15K | 177,000 |
| 13 Jun 22 | Tardugno Michael H | Option to Purchase Celsion Common Stock Celsion Corporation Common Stock | Grant | Acquire A | No | No | 1.93 | 90,000 | 173.7K | 303,068 |
| 13 Jun 22 | Church Jeffrey Wayne | Option to Purchase Celsion Common Stock Celsion Corporation Common Stock | Grant | Acquire A | No | No | 1.93 | 50,000 | 96.5K | 97,659 |
| 13 Jun 22 | Braun Donald P | Option to Purchase Celsion Common Stock Celsion Corporation Common Stock | Grant | Acquire A | No | No | 1.93 | 6,250 | 12.06K | 22,587 |
Institutional ownership, Q1 2022
0.0% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 2 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 0 |
| Total shares | 65 |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Old Second National Bank Of Aurora | 50 | $0 |
| Emerald Advisers | 15 | $0 |
Financial report summary
?Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
Anwer, beneficial, bid, BIOQUAL, biotech, calendar, cast, challenge, Charter, clear, comply, consecutive, conversion, CUSIP, dispose, DSMB, earned, effectuate, evolving, fell, fractional, highlighted, holding, hypothecate, IgG, IM, indemnification, intramuscular, Khursheed, listing, lost, Lower, methodology, murine, newer, NHP, open, oral, par, pilot, pledge, primate, receipt, redeem, Redeemable, redeemed, redemption, regain, requisite, restated, reverse, satisfactory, Science, Secretary, sector, Session, slowdown, split, strain, symbol, ticker, today, unchanged, undergone, unpaid, variant, vote, voted, voting, widest
Removed:
added, administered, admitting, affirmative, allocation, amending, approving, arranger, asserted, attributable, avoid, backed, baseline, boost, Bradford, Braun, broker, calculating, caption, Carolina, clarifying, classification, commercializing, commissioned, committed, computational, conclude, confluence, consolidate, correlation, damage, dealer, declaratory, declaring, deducting, default, DemandTM, denying, Depending, desirable, differentiation, direction, Director, discretion, disgorgement, disgorging, disruption, Docket, enrolment, entry, equivalent, excitement, exercised, exercising, existed, expedient, expiration, expired, expressed, expressly, extinguishment, fault, finally, hearing, helper, historic, humoral, improper, incorporated, incur, intramural, invalid, invalidating, judgment, lent, limit, Lincoln, liquidity, litigation, LPC, MD, merge, milliliter, mitomycin, modifier, monovalent, notice, nucleocapsid, Oppenheimer, opsonization, organized, origination, package, participated, percent, posed, project, promotion, prospective, purported, reflecting, refusal, register, regulator, remeasured, removing, renew, repayment, repricing, rescinded, return, ROU, seeking, settled, sought, South, space, Superior, surface, sustained, terminating, titled, underpinning, underwriter, underwriting, Underwritten, unequivocally, utilizing, variety, virally, virtual, Wood, wrongdoing
Financial reports
Current reports
8-K
Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer
19 Jul 22
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 22
8-K
Entry into a Material Definitive Agreement
25 May 22
8-K
Celsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update
16 May 22
8-K
Celsion Corporation Announces $7.0 Million Registered Direct Offering Priced At-the-market Under Nasdaq Rules
7 Apr 22
8-K
Celsion Corporation Reports 2021 Financial Results and Provides Business Update
31 Mar 22
8-K
Other Events
16 Mar 22
8-K
Material Modifications to Rights of Security Holders
4 Mar 22
8-K
Celsion Corporation Announces Stock Consolidation
28 Feb 22
8-K
Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock
14 Jan 22
Registration and prospectus
424B5
Prospectus supplement for primary offering
25 May 22
424B5
Prospectus supplement for primary offering
7 Apr 22
424B5
Prospectus supplement for primary offering
12 Jan 22
424B5
Prospectus supplement for primary offering
12 Jan 22
424B5
Prospectus supplement for primary offering
2 Apr 21
424B5
Prospectus supplement for primary offering
25 Jan 21
424B5
Prospectus supplement for primary offering
25 Jan 21
S-3
Shelf registration
9 Oct 20
424B5
Prospectus supplement for primary offering
8 Sep 20
Proxies
DEFA14A
Additional proxy soliciting materials
26 Jan 22
DEFA14A
Additional proxy soliciting materials
7 Jun 21
DEFA14A
Additional proxy soliciting materials
4 Jun 21
DEFA14A
Additional proxy soliciting materials
27 May 21
DEF 14A
Definitive proxy
20 Apr 21
PRER14A
Preliminary revised proxy
12 Apr 21
PRE 14A
Preliminary proxy
8 Apr 21
Other
EFFECT
Notice of effectiveness
31 Mar 21
CORRESP
Correspondence with SEC
25 Mar 21
UPLOAD
Letter from SEC
23 Mar 21
EFFECT
Notice of effectiveness
28 Oct 20
CORRESP
Correspondence with SEC
22 Oct 20
UPLOAD
Letter from SEC
15 Oct 20
EFFECT
Notice of effectiveness
14 Aug 20
CORRESP
Correspondence with SEC
10 Aug 20
UPLOAD
Letter from SEC
6 Aug 20
EFFECT
Notice of effectiveness
29 Nov 19
Ownership
4
Celsion / Goff Corinne Le ownership change
20 Jul 22
3
Celsion / Goff Corinne Le ownership change
20 Jul 22
4
Celsion / Constantine John Kardaras ownership change
15 Jun 22
4
Celsion / Timothy J Tumminello ownership change
15 Jun 22
4
Celsion / Pok Yu Augustine Chow ownership change
15 Jun 22
4
Celsion / Frederick J. Fritz ownership change
15 Jun 22
4
Celsion / Robert W Hooper ownership change
15 Jun 22
4
Celsion / Stacy Lindborg ownership change
15 Jun 22
4
Celsion / Christine A Pellizzari ownership change
15 Jun 22
4
Celsion / Donald P Braun ownership change
15 Jun 22
Transcripts
2022 Q1
Earnings call transcript
16 May 22
2021 Q4
Earnings call transcript
31 Mar 22
2021 Q3
Earnings call transcript
15 Nov 21
2021 Q2
Earnings call transcript
12 Aug 21
2021 Q1
Earnings call transcript
14 May 21
2020 Q4
Earnings call transcript
19 Mar 21
2020 Q3
Earnings call transcript
16 Nov 20
2020 Q2
Earnings call transcript
14 Aug 20
2020 Q1
Earnings call transcript
15 May 20
2019 Q4
Earnings call transcript
26 Mar 20
Reddit threads
Daily Discussion Thread - August 12th, 2022
12 Aug 22
Daily Discussion Thread - May 16th, 2022
16 May 22
Daily Discussion Thread - May 13th, 2022
13 May 22
When the F do I sell this thing you chodes told me to buy?
21 Apr 22
Daily Discussion Thread - March 31st, 2022
31 Mar 22
Daily Discussion Thread - March 30th, 2022
30 Mar 22
Daily Discussion Thread - March 29th, 2022
29 Mar 22
Daily Discussion Thread - March 25th, 2022
25 Mar 22
Daily Discussion Thread - March 24th, 2022
24 Mar 22
Daily Discussion Thread - March 23rd, 2022
23 Mar 22